EN DE
Watch Avicanna Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Avicanna Inc (AVCN) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Avicanna Inc stock C$0.10, price C$0.10, upside +2.6%, quality 28 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CA · ISIN CA05368K1003

AI Avicanna Inc logo Thin data Nov 10, 2026

Avicanna Inc

AVCN · TO
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Fair value C$0.1026 · Fairly valued
Mixed Growth (revenue 5y +74.6 %/yr in CAD)
Revenue last quarter 8% below a year ago.
Quality 28/100
Loss-making · -14.8% net margin (TTM)
Negative free cash flow
Trails peers (3/10)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Avicanna Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

C$1.08 C$0.1000 Fair Value C$0.1026 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range C$0.1000 – C$1.08 · fair‑value band C$0.0770 – C$0.1283 · the C$0.1000 price screens below the C$0.1026 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Avicanna in your weekly email

Every Wednesday you see whether Avicanna is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally.

Show moreShow less

It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific cannabinoid-based candidates to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, as well as Trunerox, an indication-specific drug treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome.

The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand.

In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement.

The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats.

Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Stock analysis

Avicanna Inc (AVCN) currently trades at C$0.1000, while our estimate is C$0.1026, so the stock looks roughly fairly valued today (gap 2.5%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: C$0.0770 (bear) to C$0.1283 (bull), the price of C$0.1000 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Avicanna Inc reported revenue of C$25.5M in FY2025 versus C$3.3M in FY2021, a compound +67.1%/yr. Reported net income was −C$2.8M in FY2025.

Key figures

Market cap C$12.6M (≈ $8.9M) Micro · P/S ratio 0.53 · EPS (TTM) C$−0.0300 · Net margin −14.8% · Return on equity −30.0% · Return on assets (EBIT) −36.5% (5-year average) · Operating margin −18.9% · Revenue (TTM) C$25.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 63% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 3%, AVCN screens cheaper than that median.

Fair Value

Bear C$0.0770 Fair Value C$0.1026 Bull C$0.1283
Price C$0.1000 · Upside +2.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 28/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 38
How much profit the company makes from its sales and capital
Quality Growth 49
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 20
Debt, balance sheet and risk of trouble
Investment 84
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 9
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+84.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+74.6%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+135.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,209.4% (2020) → −10.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch AVCN, get fair value alerts →

Compare Avicanna Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside +2.6% · Above median
Profitability
Return on assets −13.4% · Bottom 25%
Net margin (12 months) −14.8% · Bottom 25%
Operating margin (12 months) −18.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −8.4% · Below median
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 4.44× · Priciest 25%
P/S (12 months) 0.50× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)37 · sector 18
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)97 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs AVCN
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs AVCN
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs AVCN
Haleon plc HLN $9.06 $8.62 −5% vs AVCN
Merck KGaA MRK €149.35 €109.18 −27% vs AVCN
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs AVCN
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs AVCN
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs AVCN
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs AVCN
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs AVCN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Avicanna Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Avicanna Inc Fair Value". https://www.fairvalue-calculator.com/stock/AVCN

Frequently asked questions

Is Avicanna Inc (AVCN) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is C$0.1026 versus a price of C$0.1000, about +3% upside (fairly valued).
What is the fair value of AVCN?
Our estimate for Avicanna Inc is C$0.1026 (as of Nov 10, 2026), built from audited fundamentals. The current price: C$0.1000.
What is the quality score of AVCN?
Avicanna Inc has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Avicanna Inc (AVCN)?
Our calculated price target is the estimate of C$0.1026 (as of Nov 10, 2026). Cautious scenario C$0.0770, optimistic scenario C$0.1283. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Avicanna Inc stock forecast for 2026?
Our estimate puts fair value at C$0.1026, about +3% upside versus a price of C$0.1000 (fairly valued). Cautious scenario C$0.0770, optimistic scenario C$0.1283. The calculation is refreshed regularly with new filings.
What is the revenue of Avicanna Inc (AVCN)?
Avicanna Inc reported trailing-twelve-month revenue of about C$25.3M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Avicanna Inc (AVCN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Avicanna Inc it is C$0.1026 per share (as of Nov 10, 2026), against a price of C$0.1000.
Is Avicanna Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, AVCN trades below its calculated fair value: price C$0.1000, fair value C$0.1026, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AVCN?
No. The price is what the market pays today (C$0.1000); the fair value is what the company's own numbers justify (C$0.1026). For Avicanna Inc the two are C$0.0026 per share apart. That gap is exactly why we show both numbers side by side.
How much is Avicanna Inc worth?
The market values Avicanna Inc at about C$12.6M (market capitalisation, as of Nov 10, 2026). Per share that is C$0.1000; our models calculate a fair value of C$0.1026 per share.
What do the bullish and bearish scenarios say about AVCN?
Our models span a range for Avicanna Inc: cautious scenario C$0.0770, base C$0.1026, optimistic C$0.1283 per share (as of Nov 10, 2026, price C$0.1000). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Avicanna Inc (AVCN)?
Balance-sheet figures for Avicanna Inc (as of Nov 10, 2026): return on equity −30.0%, debt of 0.06 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is AVCN from its 52-week high?
Avicanna Inc trades at C$0.1000, about 63% below its 52-week high of C$0.2700 and at the low of C$0.1000 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.1026 is for.
Which stocks are comparable to Avicanna Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Avicanna Inc stock attractive at the current price?
The data as of Nov 10, 2026: price C$0.1000, calculated fair value C$0.1026 (+3%), Quality Score 28/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Avicanna Inc currently trades 3% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Avicanna Inc (AVCN)?
The closing price on Nov 10, 2026 was C$0.1000. Our estimate is C$0.1026, about +3% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Avicanna Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Avicanna Inc

How large is the market capitalisation of Avicanna Inc (AVCN)?
The market capitalisation of Avicanna Inc is C$12.6M (≈ $8.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Avicanna Inc (AVCN)?
The price-to-sales ratio of Avicanna Inc is 0.53 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Avicanna Inc (AVCN)?
Earnings per share at Avicanna Inc are C$−0.0300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Avicanna Inc (AVCN)?
The net margin of Avicanna Inc is −14.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Avicanna Inc (AVCN)?
The return on equity (ROE) of Avicanna Inc is −30.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Avicanna Inc (AVCN)?
On an EBIT basis the return on assets of Avicanna Inc is −36.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Avicanna Inc (AVCN)?
The operating margin of Avicanna Inc is −18.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Avicanna Inc (AVCN)?
Revenue at Avicanna Inc is growing −8.4% versus a year earlier (3y avg +84.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Avicanna Inc (AVCN) generate?
The free cash flow of Avicanna Inc is −C$1.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Avicanna Inc (AVCN) hold?
Avicanna Inc holds more cash than debt, C$281K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Avicanna Inc in the live analysis

One click puts Avicanna Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.